Mainstream

Exelixis outlines continued cabozantinib growth and zanzalintinib pipeline acceleration as new launches drive 19% revenue increase

Exelixis outlines continued cabozantinib growth and zanzalintinib pipeline acceleration as new launches drive 19% revenue increase

Post ContentexelRead More

You might also be interested in reading Bitcoin Recovery Sparks Hope For $73,811 Breakout, New All-Time High In Sight?.

July 29, 2025
In Mainstream